大疱性类天疱疮与瘢痕性类天疱疮  

Bullous pemphigoid and cicatricial pemphigoid

作　　者：铁·杜尔娜[1] 左亚刚[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院皮肤科,北京100730

出　　处：《国际皮肤性病学杂志》2013年第6期347-350,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81071301）;教育部新世纪优秀人才计划（NCET-10-0964）

摘　　要：通过大疱性类天疱疮与瘢痕性类天疱疮之间的比较，发现大疱性类天疱疮与瘢痕性类天疱疮之间存在相关性，表现在好发人群均为老年人、存在相同致病抗体、两者可同时合并肿瘤、间接免疫荧光显示致病抗体沉积在表皮侧等方面。近年来生物制剂如抗CD20抗体利妥昔等应用于大疱性类天疱疮与瘢痕性类天疱疮的临床治疗，具有一定疗效。瘢痕性类天疱疮的黏膜受累机制与大疱性类天疱疮180及层粘连蛋白332等自身抗体有关，发病机制尚待进一步研究。Bullous pemphigoid （BP） and cicatricial pemphigoid （CP） share some common features. For example, they both have a predilection for the elderly, and are usually complicated by tumors. Also, some pathogenic antibodies have been identified in both patients with BP and those with CP, which are demonstrated to be deposited on the epidermal side of skin by indirect immunofluorescence test. Biological agents, such as rituximab, have been applied to the treatment of BP and CP, and shown a favorable efficacy. Mechanisms underlying the mucosal involvement in CP are thought to be associated with autoantibodies such as BP180 and laminin 332, and further research is needed to clarify the pathogenesis of CP.

关 键 词：类天疱疮 大疱性 类天疱疮 良性黏膜 治疗 

分 类 号：R758.66[医药卫生—皮肤病学与性病学]